Mitoxantrone as a potential therapy for primary progressive multiple sclerosis

Olaf Stüve; Mariko Kita; Daniel Pelletier; Robert J. Fox; Jerome Stone; Donald E. Goodkin; Scott S. Zamvil

doi:10.1191/1352458504ms1032oa

Mitoxantrone as a potential therapy for primary progressive multiple sclerosis

Olaf Stüve, Mariko Kita, Daniel Pelletier, Robert J. Fox, Jerome Stone, Donald E. Goodkin, Scott S. Zamvil

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

Mitoxantrone (Novantrone®) was the first drug approved in western Europe and North America for treatment of secondary progressive multiple sclerosis (SPMS) and progressive relapsing MS (PRMS). Pharmacological properties of mitoxantrone, its role in SPMS, the study rational and design of an ongoing multi-centre, double blind, randomized, placebo-controlled phase 2 trial will be outlined in this article.

Original language	English (US)
Pages (from-to)	S58-S61
Journal	Multiple Sclerosis
Volume	10
Issue number	SUPPL. 1
DOIs	https://doi.org/10.1191/1352458504ms1032oa
State	Published - Jun 2004

Keywords

Genetics
Immunology
Magnetic resonance imaging
Multiple sclerosis
Pathology
Primary progressive
Therapies

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1191/1352458504ms1032oa

Cite this

@article{88a642e7d69b4c7da19a8b9bc2892a12,

title = "Mitoxantrone as a potential therapy for primary progressive multiple sclerosis",

abstract = "Mitoxantrone (Novantrone{\textregistered}) was the first drug approved in western Europe and North America for treatment of secondary progressive multiple sclerosis (SPMS) and progressive relapsing MS (PRMS). Pharmacological properties of mitoxantrone, its role in SPMS, the study rational and design of an ongoing multi-centre, double blind, randomized, placebo-controlled phase 2 trial will be outlined in this article.",

keywords = "Genetics, Immunology, Magnetic resonance imaging, Multiple sclerosis, Pathology, Primary progressive, Therapies",

author = "Olaf St{\"u}ve and Mariko Kita and Daniel Pelletier and Fox, {Robert J.} and Jerome Stone and Goodkin, {Donald E.} and Zamvil, {Scott S.}",

year = "2004",

month = jun,

doi = "10.1191/1352458504ms1032oa",

language = "English (US)",

volume = "10",

pages = "S58--S61",

journal = "Multiple Sclerosis",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "SUPPL. 1",

}

TY - JOUR

T1 - Mitoxantrone as a potential therapy for primary progressive multiple sclerosis

AU - Stüve, Olaf

AU - Kita, Mariko

AU - Pelletier, Daniel

AU - Fox, Robert J.

AU - Stone, Jerome

AU - Goodkin, Donald E.

AU - Zamvil, Scott S.

PY - 2004/6

Y1 - 2004/6

N2 - Mitoxantrone (Novantrone®) was the first drug approved in western Europe and North America for treatment of secondary progressive multiple sclerosis (SPMS) and progressive relapsing MS (PRMS). Pharmacological properties of mitoxantrone, its role in SPMS, the study rational and design of an ongoing multi-centre, double blind, randomized, placebo-controlled phase 2 trial will be outlined in this article.

AB - Mitoxantrone (Novantrone®) was the first drug approved in western Europe and North America for treatment of secondary progressive multiple sclerosis (SPMS) and progressive relapsing MS (PRMS). Pharmacological properties of mitoxantrone, its role in SPMS, the study rational and design of an ongoing multi-centre, double blind, randomized, placebo-controlled phase 2 trial will be outlined in this article.

KW - Genetics

KW - Immunology

KW - Magnetic resonance imaging

KW - Multiple sclerosis

KW - Pathology

KW - Primary progressive

KW - Therapies

UR - http://www.scopus.com/inward/record.url?scp=3042643912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042643912&partnerID=8YFLogxK

U2 - 10.1191/1352458504ms1032oa

DO - 10.1191/1352458504ms1032oa

M3 - Article

C2 - 15218811

AN - SCOPUS:3042643912

SN - 1352-4585

VL - 10

SP - S58-S61

JO - Multiple Sclerosis

JF - Multiple Sclerosis

IS - SUPPL. 1

ER -

Mitoxantrone as a potential therapy for primary progressive multiple sclerosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this